PHILADELPHIA, May 25 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a leading provider of centralized electrocardiographic (ECG) services and clinical data technology and services, today updated its new signings outlook. The company expects new contract signings of $31 million to $34 million in the second quarter.
eRT provides comprehensive support, including provision of digital 12-lead ECG equipment designed to facilitate collection of cardiac safety data that is subsequently provided to eRT for analysis. eRT performs digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT(R) workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. In addition, the company provides electronic data capture (EDC), portal, and back office applications technology and services.
“The Company’s second quarter outlook of $31 million to $34 million is expected to include two to three significant later phase development programs, seven to nine Thorough ECG Trials (TET), and two significant agreements for EDC, portal, and back office technologies and services,” said Scott Grisanti, executive vice president of business development and chief marketing officer at eRT. “Our balanced performance in the quarter is tracking to be up from the first quarter of this year and over 20% compared to last year. The Company’s consistent signings activity over the past three quarters signals strong revenue growth in the second half of this year as the new business converts to revenue.”
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company’s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company’s financial results can be
found in the company’s Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission.
eResearchTechnology, Inc.
CONTACT: Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; orMatt Hayden, Hayden Communications, +1-858-704-5065, foreResearchTechnology
Web site: http://www.ert.com/
